APROS-ÜREME-V1.0: KADIN ÜREME SAĞLIĞI İÇİN OVER YAŞLANMASINI YAVAŞLATMA PROTOKOLÜ (ALTERNATİF TÜM MEKANİZMALAR)

This is a defensive publication (prior art disclosure) titled "APROS-ÜREME-V2.0: Over Yaşlanmasını Yavaşlatma ve Menopozu Geciktirme Protokolü".

The document discloses all alternative technical approaches to slow down ovarian aging, delay menopause, and preserve ovarian reserve, including:

1. mTOR inhibition (Rapamycin and its analogs)

2. Epigenetic reset (ovary-specific OSKM modified mRNA, APROS F2 integration)

3. Stem cell therapies (mesenchymal stem cells, ovarian stem cell activation)

4. Anti-aging agents (Metformin, NAD+ precursors, mitophagy activators)

5. Gene editing (CRISPR-Cas9 targeting p16, CRISPRa activating FOXO3a/SIRT1)

6. Nanoparticle-based ovarian targeting (APROS-NANO integration with 7 layers)

The document establishes prior art against any patent claiming ovarian aging delay or menopause postponement via the mechanisms described herein. All obvious variations (doe ±20%, vector substitution, route changes, homologous sequences >80%) are explicitly covered under KSR v. Teleflex (2007).

This work is licensed under CC BY-NC-SA 4.0. Non-commercial use by public hospitals, universities, and research institutions is permitted. Commercial use (patenting or selling by pharmaceutical companies) is prohibited.

Keywords: ovarian aging, menopause delay, ovarian reserve, APROS, OSKM, epigenetic reset, Rapamycin, metformin, NAD+, CRISPR, mesenchymal stem cells, targeted nanoparticle, defensive publication, prior art.

Anahtar kelimeler